Table 1

Study characteristics

Study characteristicN (%) (n=180)
Sponsor
 Commercial90 (50.0)
 Non-commercial81 (45.0)
 Unknown9 (5.0)
Type of study
 Parallel group164 (91.1)
 Cluster11 (6.1)
 Crossover5 (2.8)
Multicountry45 (25.0)
 Number of countries in multicountry studies—median (IQR)7 (3–11)
Included modality
 Haemodialysis147 (81.7)
 Both hemodialysis and peritoneal dialysis17 (9.4)
 Peritoneal dialysis16 (8.9)
Number of participants – median (IQR)208 (148–334)
Number of sites – median (IQR)15 (5–38)
Planned duration of follow-up (months) – median (IQR)7 (3–12)